April 24, 2023 Valitor Presents Preclinical Data on its Long-acting Anti-VEGF Biologic in Development for Durable Treatment of Wet AMD at the Association for Research in Vision and Ophthalmology Annual Meeting
April 10, 2023 Valitor to Present on the Potential for its Multivalent Polymer Technology to Expand the Therapeutic Index of Oncology Agents at the 2023 American Association for Cancer Research Annual Meeting
March 23, 2023 Valitor to Present at the Association for Research in Vision and Ophthalmology Annual Meeting
December 01, 2022 Valitor Announces Presentation on Novel Anti-VEGF Antibody Conjugate and Multivalent Polymer Technology Platform at Upcoming Ophthalmology Innovation Source (OIS) Summit - Preclinical data support twice-yearly dosing in wet AMD -
October 05, 2022 Valitor Announces the Closing of its Series B Financing and Names Steven Lo as Chief Executive Officer
